| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/21/2002 | WO2002022807A2 Dermatophagoides nucleic acid molecules, proteins and uses thereof |
| 03/21/2002 | WO2002022806A2 Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses tehreof |
| 03/21/2002 | WO2002022805A2 Modulation of il-2- and il-15-mediated t cell responses |
| 03/21/2002 | WO2002022795A2 Isolated human kinase proteins, nucleic acid molecules and uses thereof |
| 03/21/2002 | WO2002022685A2 Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
| 03/21/2002 | WO2002022684A2 Transporters and ion channels |
| 03/21/2002 | WO2002022682A1 Interferon-alpha induced gene |
| 03/21/2002 | WO2002022678A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/21/2002 | WO2002022677A2 Variants of allergenic proteins of the group 2 of dermatophagoides |
| 03/21/2002 | WO2002022655A1 Glutathione conjugates with distamycin derivatives having antitumoral activity |
| 03/21/2002 | WO2002022610A1 Isoxazoles and their use as inhibitors of erk |
| 03/21/2002 | WO2002022608A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022607A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022606A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022605A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022604A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022603A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022602A2 Triazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022601A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022584A1 Thrombin inhibitors |
| 03/21/2002 | WO2002022573A2 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
| 03/21/2002 | WO2002022212A2 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 03/21/2002 | WO2002022188A1 Peritoneal dialysates |
| 03/21/2002 | WO2002022175A2 Method and composition for treating tumors by selective induction of apoptosis |
| 03/21/2002 | WO2002022174A1 A novel cationic lipopolymer as biocompatible gene delivery agent |
| 03/21/2002 | WO2002022171A2 Pharmaceutical composition having specific water activity |
| 03/21/2002 | WO2002022166A2 Tweak receptor agonists as anti-angiogenic agents |
| 03/21/2002 | WO2002022161A2 The diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases |
| 03/21/2002 | WO2002022160A2 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
| 03/21/2002 | WO2002022159A1 Thionin as an antineoplastic and immunostimulant |
| 03/21/2002 | WO2002022151A2 Use of glp-1 and flp-2 peptides for treatment of bone disorders |
| 03/21/2002 | WO2002022150A2 Medicament containing activated antithrombin iii |
| 03/21/2002 | WO2002022147A1 Antibacterial combination comprising neem plant extract |
| 03/21/2002 | WO2002022142A1 Cough depressant composition containing iron for angiotensin-converting enzyme inhibitor inducing cough |
| 03/21/2002 | WO2002022134A1 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals |
| 03/21/2002 | WO2002022129A1 A method of analgesia |
| 03/21/2002 | WO2002022127A1 Use of phosphodiesterase inhibitors for the treatment of anorectal disorders |
| 03/21/2002 | WO2002022124A1 Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist |
| 03/21/2002 | WO2002022123A1 Alpha v integrin receptor antagonists |
| 03/21/2002 | WO2002022120A1 Pain reliever and method of use |
| 03/21/2002 | WO2002022114A2 Methods and compositions for the treatment and prevention of sexual dysfunction |
| 03/21/2002 | WO2002022112A2 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 03/21/2002 | WO2002022110A2 Contraception process and administration form for the same |
| 03/21/2002 | WO2002022108A1 Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
| 03/21/2002 | WO2002022107A2 Pharmaceutical composition having modified carrier |
| 03/21/2002 | WO2002022088A1 Hair nourishments and method of screening the same |
| 03/21/2002 | WO2002022087A1 Compositions containing a vitamin c component and pigment |
| 03/21/2002 | WO2002022077A2 Compositions and methods for inhibition of hiv-1 infection |
| 03/21/2002 | WO2002021996A2 Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators |
| 03/21/2002 | WO2002000024A8 New strategy for leukemia therapy |
| 03/21/2002 | WO2001095920A8 Composition comprising clinoptolite, plant extracts and vitamin b complex for diabetic neuropathy |
| 03/21/2002 | WO2001083457A3 Benzimidazole-2-carbamates and their use in cancer treatment |
| 03/21/2002 | WO2001080829A3 Taste masking coating composition |
| 03/21/2002 | WO2001078760A3 Method for treating pain by peripheral administration of a neurotoxin |
| 03/21/2002 | WO2001074379A3 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors |
| 03/21/2002 | WO2001072841A3 Isolated human g-protein coupled receptors that are members of the aminergic subfamily, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 03/21/2002 | WO2001072840A3 Isolated human g-protein coupled receptors of the mas proto-oncogene subfamily, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 03/21/2002 | WO2001068861A3 THREE-DIMENSIONAL MODEL OF A Fc REGION OF AN IgE ANTIBODY AND USES THEREOF |
| 03/21/2002 | WO2001068123A3 Monocyte chemoattractant activity of galectin-3 |
| 03/21/2002 | WO2001064837A3 β NETRIN AND USES THEREOF |
| 03/21/2002 | WO2001064252A3 Farnesyl protein transferase inhibitor combinations with further anti-cancer agents |
| 03/21/2002 | WO2001064218A3 Farnesyl protein transferase inhibitor combinations |
| 03/21/2002 | WO2001064198A3 Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
| 03/21/2002 | WO2001064197A3 Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| 03/21/2002 | WO2001064196A3 Farnesyl protein transferase inhibitor combinations with vinca alkaloids |
| 03/21/2002 | WO2001064195A3 Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives |
| 03/21/2002 | WO2001062942A3 MATERIALS AND METHODS INVOLVING HYBRID VASCULAR ENDOTHELIAL GROWTH FACTOR DNAs AND PROTEINS AND SCREENING METHODS FOR MODULATORS |
| 03/21/2002 | WO2001062905A3 Integrin antagonists |
| 03/21/2002 | WO2001062725A3 Methods and compositions for inhibiting angiogenesis |
| 03/21/2002 | WO2001060991A3 Human kinases |
| 03/21/2002 | WO2001051638A3 Drug metabolizing enzymes |
| 03/21/2002 | WO2001051055A3 Pharmaceutical compositions containing steroidal structures and uses thereof |
| 03/21/2002 | WO2001043732A3 Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies |
| 03/21/2002 | WO2001043731A3 Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage |
| 03/21/2002 | WO2001041749A3 Combinations of sumatriptan or naratriptan with cyclooxygenase iiinhibitor |
| 03/21/2002 | WO2001038567A3 Genetic indicators of tobacco consumption |
| 03/21/2002 | WO2001037779A3 A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer |
| 03/21/2002 | WO2001035943A3 Dextrose and insulin fluid formulation for intravenous infusion |
| 03/21/2002 | WO2001034135A3 Oncolytic combinations for the treatment of cancer |
| 03/21/2002 | WO2001030375A3 Use of gdnf for treating corneal defects |
| 03/21/2002 | WO2001012176A3 Use of monoamine oxidase inhibitors for the manufacture of drugs intended for the treatment of obesity |
| 03/21/2002 | WO2001003774A3 Pharmaceutical composition for the treatment of calcification |
| 03/21/2002 | US20020035734 Binding protein for use in the treatment of neutropenia, infections and cancer |
| 03/21/2002 | US20020035394 Methods and apparatus for stenting comprising enhanced embolic protection, coupled with improved protection against restenosis and thrombus formation |
| 03/21/2002 | US20020035264 Therapy for vision disorders |
| 03/21/2002 | US20020035240 Novel mammalian cell cycle protein |
| 03/21/2002 | US20020035161 O/W emulsions comprising micronized biologically active agents |
| 03/21/2002 | US20020035157 Mixture containing vasodilator |
| 03/21/2002 | US20020035153 Kits; containing a compound containing an oxamic acid group |
| 03/21/2002 | US20020035150 Adminstering a cannabinoid compound |
| 03/21/2002 | US20020035145 Administering mixture of alanine, serine, methylglycine and cycloserine |
| 03/21/2002 | US20020035139 COX-2 inhibitors and the prevention of the side effects of radiation therapy |
| 03/21/2002 | US20020035126 Side effect reduction |
| 03/21/2002 | US20020035125 Therapeutic combination |
| 03/21/2002 | US20020035110 Treatment or prevention of disorders of the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, and sleep apnea |
| 03/21/2002 | US20020035108 Method for treating allergies |
| 03/21/2002 | US20020035105 Composition and method combining an antidepressant with an NMDA receptor antagonist, for treating neuropathic pain |
| 03/21/2002 | US20020035099 That are antagonists of the progesterone receptor, in a female contraceptive kit |
| 03/21/2002 | US20020035093 Methods for the administration of amifostine and related compounds |
| 03/21/2002 | US20020035090 Compositions and methods for the treatment of cancer |